The International Council for Harmonisation is making significant changes to its draft E19 guideline, which proposes limiting the collection of safety data in some late-stage pre or postmarketing studies when the safety profile of a drug is sufficiently characterized.
The guideline is being “re-written considerably” to address the “extensive comments” it drew from stakeholders, including notably some EU competent authorities, when it was issued for public consultation last year,...